BR112022020944A2 - Variantes de anticorpos caninos - Google Patents
Variantes de anticorpos caninosInfo
- Publication number
- BR112022020944A2 BR112022020944A2 BR112022020944A BR112022020944A BR112022020944A2 BR 112022020944 A2 BR112022020944 A2 BR 112022020944A2 BR 112022020944 A BR112022020944 A BR 112022020944A BR 112022020944 A BR112022020944 A BR 112022020944A BR 112022020944 A2 BR112022020944 A2 BR 112022020944A2
- Authority
- BR
- Brazil
- Prior art keywords
- canine antibody
- antibody variants
- canine
- variants
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011453P | 2020-04-17 | 2020-04-17 | |
| PCT/US2021/027836 WO2021212081A1 (en) | 2020-04-17 | 2021-04-16 | Canine antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020944A2 true BR112022020944A2 (pt) | 2022-12-27 |
Family
ID=75888187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020944A BR112022020944A2 (pt) | 2020-04-17 | 2021-04-16 | Variantes de anticorpos caninos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230242635A1 (https=) |
| EP (1) | EP4136106A1 (https=) |
| JP (1) | JP2023522029A (https=) |
| KR (1) | KR20230005156A (https=) |
| CN (1) | CN115996949A (https=) |
| AU (1) | AU2021256056A1 (https=) |
| BR (1) | BR112022020944A2 (https=) |
| CA (1) | CA3175921A1 (https=) |
| CL (2) | CL2022002857A1 (https=) |
| CO (1) | CO2022014695A2 (https=) |
| EC (1) | ECSP22080846A (https=) |
| IL (1) | IL297287A (https=) |
| MX (1) | MX2022012866A (https=) |
| PE (1) | PE20230108A1 (https=) |
| PH (1) | PH12022552742A1 (https=) |
| TW (1) | TW202204403A (https=) |
| WO (1) | WO2021212081A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112020002871A2 (pt) | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| US11542333B2 (en) | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| US11434276B2 (en) | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| IL301413A (en) * | 2020-09-28 | 2023-05-01 | Zoetis Services Llc | Canine antibody variants |
| KR20250026186A (ko) * | 2022-06-21 | 2025-02-25 | 조에티스 서비시즈 엘엘씨 | 갯과 항체 돌연변이체 |
| JP2026508096A (ja) | 2023-01-20 | 2026-03-10 | ゾエティス・サービシーズ・ユーケー・リミテッド | 治療抗体 |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| RS61723B1 (sr) * | 2011-02-04 | 2021-05-31 | Zoetis Services Llc | Imunogenične bordetella bronchiseptica kompozicije |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| CN114773470A (zh) * | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| KR20230079500A (ko) * | 2015-09-18 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8에 결합하는 항체 및 그의 사용 |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| TWI693940B (zh) * | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| WO2018073185A1 (en) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CN113194984A (zh) * | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| US11542333B2 (en) * | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| US20220169740A1 (en) * | 2019-03-20 | 2022-06-02 | Kindred Biosciences, Inc. | NGF Antagonists for Medical Use |
| IL301413A (en) * | 2020-09-28 | 2023-05-01 | Zoetis Services Llc | Canine antibody variants |
| WO2022165067A2 (en) * | 2021-01-28 | 2022-08-04 | Zoetis Services Llc | Mutations in canine antibody constant regions |
-
2021
- 2021-04-16 CN CN202180028973.4A patent/CN115996949A/zh active Pending
- 2021-04-16 EP EP21724863.2A patent/EP4136106A1/en active Pending
- 2021-04-16 JP JP2022562645A patent/JP2023522029A/ja active Pending
- 2021-04-16 IL IL297287A patent/IL297287A/en unknown
- 2021-04-16 MX MX2022012866A patent/MX2022012866A/es unknown
- 2021-04-16 PE PE2022002420A patent/PE20230108A1/es unknown
- 2021-04-16 CA CA3175921A patent/CA3175921A1/en active Pending
- 2021-04-16 AU AU2021256056A patent/AU2021256056A1/en active Pending
- 2021-04-16 KR KR1020227035765A patent/KR20230005156A/ko active Pending
- 2021-04-16 BR BR112022020944A patent/BR112022020944A2/pt unknown
- 2021-04-16 US US17/918,853 patent/US20230242635A1/en active Pending
- 2021-04-16 WO PCT/US2021/027836 patent/WO2021212081A1/en not_active Ceased
- 2021-04-16 PH PH1/2022/552742A patent/PH12022552742A1/en unknown
- 2021-04-19 TW TW110113947A patent/TW202204403A/zh unknown
-
2022
- 2022-10-17 EC ECSENADI202280846A patent/ECSP22080846A/es unknown
- 2022-10-17 CL CL2022002857A patent/CL2022002857A1/es unknown
- 2022-10-18 CO CONC2022/0014695A patent/CO2022014695A2/es unknown
-
2023
- 2023-11-13 CL CL2023003377A patent/CL2023003377A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022012866A (es) | 2022-11-08 |
| US20230242635A1 (en) | 2023-08-03 |
| TW202204403A (zh) | 2022-02-01 |
| ECSP22080846A (es) | 2023-02-28 |
| KR20230005156A (ko) | 2023-01-09 |
| JP2023522029A (ja) | 2023-05-26 |
| CA3175921A1 (en) | 2021-10-21 |
| WO2021212081A1 (en) | 2021-10-21 |
| AU2021256056A1 (en) | 2022-10-20 |
| PE20230108A1 (es) | 2023-01-25 |
| PH12022552742A1 (en) | 2024-03-25 |
| IL297287A (en) | 2022-12-01 |
| EP4136106A1 (en) | 2023-02-22 |
| CL2023003377A1 (es) | 2024-04-19 |
| CN115996949A (zh) | 2023-04-21 |
| CO2022014695A2 (es) | 2022-10-21 |
| CL2022002857A1 (es) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020944A2 (pt) | Variantes de anticorpos caninos | |
| BR112023005393A2 (pt) | Variantes de anticorpos caninos | |
| BR112022011032A2 (pt) | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo | |
| ECSP22080858A (es) | Variantes de anticuerpos felinos | |
| CY1118896T1 (el) | Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9 | |
| BR112014005799A2 (pt) | anticorpos para pcsk9, seus usos, e composição farmacêutica | |
| CO2023007829A2 (es) | Mutaciones en regiones constantes de anticuerpos felinos | |
| BR112023017728A2 (pt) | Anticorpos anti-nectin-4 e uso dos mesmos | |
| PE20191476A1 (es) | Nueva formulacion estable de anticuerpos anti-fxia | |
| BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson | |
| CL2024001562A1 (es) | Mutaciones en regiones constantes de anticuerpos caninos. | |
| BR112023008490A2 (pt) | Variantes de anticorpo bovino | |
| BR112018008900A2 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
| MX2024015391A (es) | Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico | |
| BR112021021060A2 (pt) | Anticorpos anti-cd38 e formulações | |
| CL2024000789A1 (es) | Variantes de anticuerpos felinos. | |
| BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
| BR112022000005A2 (pt) | Agentes de ligação a cd38 e usos dos mesmos | |
| EA202192532A1 (ru) | Мирикизумаб для применения в способе лечения болезни крона | |
| BR112022012584A2 (pt) | Compostos e derivados de hidroxiestilbeno substituído, síntese e uso deles | |
| BR112016001009A2 (pt) | nova proteína de ornitina descarboxilase modificada e sua utilização | |
| TH161998A (th) | แอนติบอดีต่อ pcsk9 และการใช้ของมัน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024006370-0 PROTOCOLO 870240028089 EM 01/04/2024 12:54. |